Cardiol Therapeutics Receivables

Cardiol Therapeutics (CRDL) currently reports a receivables of $340K as of March 2026. That compares with $350K in the prior-year period — down 1.8% year over year. Use the charts on this page to explore Cardiol Therapeutics's receivables history and peer comparisons.

Cardiol Therapeutics's receivables decreased from $350K to $340K — a 1.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cardiol Therapeutics reported $340K in receivables as of March 2026. That compares with $350K in the prior-year period — down 1.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $340K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cardiol Therapeutics, and consider following CRDL for alerts when major investors trade the stock.

Cardiol Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $340K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRDL with unrelated industries.